PPAR-γ agonists further ameliorated lipid-induced polarization of inflammatory KCs in mice resulting in an improvement of steatohepatitis (158) and also reduced components of NASH in a long term clinical study (159). Here, TBCE is linked to metabolic dysfunction-associated steatohepatitis.